Adrianna Ratajska1, Bonnie I Glanz2, Tanuja Chitnis2, Howard L Weiner2, Brian C Healy3. 1. Partners Multiple Sclerosis Center, Brigham and Women's Hospital, Boston, MA, United States of America; Department of Clinical and Health Psychology, University of Florida, Gainesville, FL, United States of America. 2. Partners Multiple Sclerosis Center, Brigham and Women's Hospital, Boston, MA, United States of America; Department of Neurology, Harvard Medical School, Boston, MA, United States of America. 3. Partners Multiple Sclerosis Center, Brigham and Women's Hospital, Boston, MA, United States of America; Department of Neurology, Harvard Medical School, Boston, MA, United States of America; Biostatistics Center, Massachusetts General Hospital, Boston, MA, United States of America. Electronic address: bchealy@mgh.harvard.edu.
Abstract
OBJECTIVE: Social support plays a role in the well-being of persons with multiple sclerosis (PwMS). The aims of this study were to compare social support in PwMS with relapsing versus progressive disease, examine the relationships with patient reported outcomes (PROs), and investigate social support longitudinally. METHODS: For this study, we have performed an analysis of data routinely collected from subjects enrolled in the CLIMB at the Partners MS Center. Subjects (n = 789) completed measures of social support, quality of life (QOL), depression, and anxiety. Relapsing and progressive PwMS were compared using a two sample t-test, and linear regression was used to adjust for other variables. Correlations between social support and PROs were assessed using partial Pearson's correlation coefficient. A random intercept and slope model with a linear trend with time estimated the change over time. RESULTS: Subjects with relapsing MS reported higher overall social support than subjects with progressive disease (difference in means = -6.7; 95% CI: -10.3, -3.1) as well as higher levels of 3 of the 4 dimensions of social support measured. These differences remained after adjusting for age and gender only, but were attenuated adjusting for age, gender, and depression (adjusted difference in means = -1.2; 95% CI: -5.0, 2.6). Higher overall social support was associated with higher QOL (r = 0.16-0.27), lower depression (r = -0.36), and lower state (r = -0.27) and trait (r = -0.29) anxiety. Social support was mostly stable over time. CONCLUSION: Social support was associated with QOL, depression, and anxiety in PwMS.
OBJECTIVE: Social support plays a role in the well-being of persons with multiple sclerosis (PwMS). The aims of this study were to compare social support in PwMS with relapsing versus progressive disease, examine the relationships with patient reported outcomes (PROs), and investigate social support longitudinally. METHODS: For this study, we have performed an analysis of data routinely collected from subjects enrolled in the CLIMB at the Partners MS Center. Subjects (n = 789) completed measures of social support, quality of life (QOL), depression, and anxiety. Relapsing and progressive PwMS were compared using a two sample t-test, and linear regression was used to adjust for other variables. Correlations between social support and PROs were assessed using partial Pearson's correlation coefficient. A random intercept and slope model with a linear trend with time estimated the change over time. RESULTS: Subjects with relapsing MS reported higher overall social support than subjects with progressive disease (difference in means = -6.7; 95% CI: -10.3, -3.1) as well as higher levels of 3 of the 4 dimensions of social support measured. These differences remained after adjusting for age and gender only, but were attenuated adjusting for age, gender, and depression (adjusted difference in means = -1.2; 95% CI: -5.0, 2.6). Higher overall social support was associated with higher QOL (r = 0.16-0.27), lower depression (r = -0.36), and lower state (r = -0.27) and trait (r = -0.29) anxiety. Social support was mostly stable over time. CONCLUSION: Social support was associated with QOL, depression, and anxiety in PwMS.
Authors: Anne Kever; Korhan Buyukturkoglu; Claire S Riley; Philip L De Jager; Victoria M Leavitt Journal: J Neurol Date: 2021-01-03 Impact factor: 4.849
Authors: Jessica Podda; Michele Messmer Uccelli; Andrea Tacchino; Ludovico Pedullà; Margherita Monti Bragadin; Mario Alberto Battaglia; Giampaolo Brichetto; Michela Ponzio Journal: Int J MS Care Date: 2022-06-20
Authors: Yibin Ao; Hao Zhu; Fanrong Meng; Yan Wang; Gui Ye; Linchuan Yang; Na Dong; Igor Martek Journal: Int J Environ Res Public Health Date: 2020-12-06 Impact factor: 3.390